<DOC>
	<DOCNO>NCT01730027</DOCNO>
	<brief_summary>This randomise , double-blind , placebo-controlled study evaluate efficacy safety ADC3680 administer daily add-on therapy inhale corticosteroid co-administered montelukast patient inadequately-controlled asthma . Patients randomise 3 Arms receive ADC3680 , placebo montelukast .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety ADC3680 Subjects With Inadequately-Controlled Asthma</brief_title>
	<detailed_description>This multi-centre , randomised , placebo-controlled , double blind , parallel group 3-arm study ( include montelukast active comparator ) design compare efficacy safety daily dose ADC3680 placebo subject inadequately-controlled asthma despite receive low moderate dose ICS controller therapy , 10 week treatment period . At end 10 week treatment period open label montelukast ( 10 mg ) add ADC3680 placebo arm two week extension period ass whether efficacy ADC3680 enhance addition montelukast compare montelukast alone . The montelukast arm continue 10 mg montelukast alone .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Men woman age 18 year 50 year ( inclusive ) Diagnosis asthma ( GINA 2011 ) include demonstration reversible airway obstruction Prebronchodilator FEV1 value ≥ 40 % ≤ 85 % predict normal value baseline A score 1.5 great Asthma Control Questionnaire baseline Daily use low moderate dose ICS ( equivalent budesonide ≤ 800 µg per day ) Prescribed shortacting inhaled bronchodilator reliever therapy relief symptom A peripheral blood eosinophil count ≥ 0.25 x 109/L Nonsmoker former smoker smoke last six month Body mass index ( BMI ) ≥ 17 ≤ 35 kg/m2 Able comply protocol requirement , instruction restriction Able provide sign dated write informed consent Subjects severe asthma exacerbation 4 week prior consent Subjects respiratory tract infection 4 week prior consent Subjects COPD relevant lung diseases Subjects clinically significant condition may compromise subject safety interfere study evaluation Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>